림프액 부종 치료 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 치료법별, 이환 부위별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Lymphedema Treatment Market Summary

The global lymphedema treatment market size was valued at USD 8.8 billion in 2025 and is projected to grow from USD 9.5 billion in 2026 to USD 16.6 billion by 2033, at a CAGR of 8.3% from 2026 to 2033. North America held the largest global revenue share of 42.4% in 2025. The growth of the lymphedema treatment industry is driven by the rising prevalence of secondary lymphedema associated with cancer treatments, particularly breast cancer surgeries and radiation therapy, along with growing awareness and earlier diagnosis of the condition.

The increasing adoption of compression therapy products, pneumatic compression devices, and emerging surgical interventions is driving market growth. In addition, expanding healthcare access and ongoing advancements in treatment technologies are improving patient outcomes and creating new opportunities within the market. According to Breastcancer.org, in 2026, it is estimated that about 42,140 women in the U.S. will die from breast cancer, highlighting the continuing mortality burden of the disease despite advances in early detection and treatment.

The rising prevalence of cancer-related lymphedema is a major driver of the lymphedema treatment market, as increasing numbers of cancer survivors require long-term management following lymph node dissection and radiation therapy. Breast cancer patients represent the largest affected group, although lymphedema is also common among survivors of gynecological, prostate, melanoma, and head and neck cancers. Improvements in cancer survival rates have expanded the patient population at risk of developing secondary lymphedema, driving demand for compression therapies, pneumatic compression devices, rehabilitation services, and surgical interventions.

Global Lymphedema Treatment Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global lymphedema treatment market report based on type, treatment type, affected area, end-use, and region:

• Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Secondary Lymphedema
  • Cancer-related Lymphedema
  • Non-cancer-related Lymphedema
• Primary Lymphedema
• Treatment Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Conservative/Non-invasive Therapy
  • Compression Garments & Stockings
  • Compression Bandages & Wraps
  • Manual Lymphatic Drainage (MLD)
  • Therapeutic Exercise & Complete Decongestive Therapy (CDT)
  • Kinesiology Taping
• Medical Devices
  • Sequential Pneumatic Compression Devices (SPCDs)
  • Low-Level Laser Therapy (LLLT) Devices
  • Advanced Compression Systems
• Surgical Interventions
  • Lymphovenous Anastomosis (LVA)
  • Vascularized Lymph Node Transfer (VLNT)
  • Liposuction & Debulking Procedures
• Pharmacological Therapy
• Affected Area Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Upper Extremity Lymphedema
• Lower Extremity Lymphedema
• Head & Neck Lymphedema
• Genital & Truncal Lymphedema
• End-use Outlook (Revenue, USD Million/Billion; 2021 - 2033)
• Hospitals
• Lymphedema Treatment Centers & Rehabilitation Clinics
• Ambulatory Surgical Centers (ASCs)
• Home Care Settings
• Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type
  • 1.1.2. Treatment Type
  • 1.1.3. Affected Area
  • 1.1.4. End Use
  • 1.1.5. Regional scope
  • 1.1.6. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Lymphedema Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
• 3.2. Pipeline Analysis
  • 3.2.1. Pipeline products by:
    • 3.2.1.1. Type (biologics, devices)
    • 3.2.1.2. Stage of development
  • 3.2.2. Emerging technologies:
    • 3.2.2.1. Growth factors
    • 3.2.2.2. Stem cell therapy
    • 3.2.2.3. Advanced wound dressings
  • 3.2.3. Innovation trends and approvals
• 3.3. Market Dynamics
  • 3.3.1. Market driver analysis
    • 3.3.1.1. Rising prevalence of cancer-related lymphedema
    • 3.3.1.2. Increasing cancer survivorship rates
    • 3.3.1.3. Growing awareness and early diagnosis
    • 3.3.1.4. Technological advancements in compression devices
  • 3.3.2. Market restraint analysis
    • 3.3.2.1. High treatment costs
    • 3.3.2.2. Shortage of certified lymphedema therapists
  • 3.3.3. Market opportunity analysis
    • 3.3.3.1. Growth in home-based care
    • 3.3.3.2. Expansion in emerging markets
    • 3.3.3.3. Development of smart compression technologies
    • 3.3.3.4. Advances in microsurgical techniques
  • 3.3.4. Market challenge analysis
    • 3.3.4.1. Underdiagnosis and delayed treatment
    • 3.3.4.2. Poor long-term adherence
• 3.4. Lymphedema Treatment Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Bargaining power of suppliers
    • 3.4.1.2. Bargaining power of buyers
    • 3.4.1.3. Threat of substitutes
    • 3.4.1.4. Threat of new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political & Legal Landscape
    • 3.4.2.2. Economic and Social Landscape
    • 3.4.2.3. Technological landscape

Chapter 4. Lymphedema Treatment Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Lymphedema Treatment: Type Movement Analysis
• 4.3. Global Lymphedema Treatment Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million/Billion)
• 4.4. Secondary Lymphedema
  • 4.4.1. Secondary lymphedema market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 4.4.2. Cancer-related lymphedema
    • 4.4.2.1. Cancer-related lymphedema market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 4.4.3. Non-cancer-related lymphedema
    • 4.4.3.1. Non-cancer-related lymphedema market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
• 4.5. Primary Lymphedema
  • 4.5.1. Primary lymphedema market estimates and forecasts for 2021 to 2033 (USD Million/Billion)

Chapter 5. Lymphedema Treatment Market: Treatment Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Lymphedema Treatment Market: Treatment Type Movement Analysis
• 5.3. Global Lymphedema Treatment Market Size & Trend Analysis, by Treatment Type, 2021 to 2033 (USD Million/Billion)
• 5.4. Conservative/Non-invasive Therapy
  • 5.4.1. Conservative/non-invasive therapy market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 5.4.2. Compression garments & stockings
    • 5.4.2.1. Compression garments & stockings market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 5.4.3. Compression bandages & wraps
    • 5.4.3.1. Compression bandages & wraps market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 5.4.4. Manual lymphatic drainage (MLD)
    • 5.4.4.1. Manual lymphatic drainage (MLD) market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 5.4.5. Therapeutic exercise & complete decongestive therapy (CDT)
    • 5.4.5.1. Therapeutic exercise & complete decongestive therapy (CDT) market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 5.4.6. Kinesiology taping
    • 5.4.6.1. Kinesiology taping market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
• 5.5. Medical devices
  • 5.5.1. Medical devices market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 5.5.2. Sequential pneumatic compression devices (SPCDs)
    • 5.5.2.1. Sequential pneumatic compression devices (SPCDs) market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 5.5.3. Low-level laser therapy (LLLT) devices
    • 5.5.3.1. Low-level laser therapy (LLLT) devices market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 5.5.4. Advanced compression systems
    • 5.5.4.1. Advanced compression systems market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
• 5.6. Surgical interventions
  • 5.6.1. Surgical interventions market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 5.6.2. Lymphovenous anastomosis (LVA)
    • 5.6.2.1. Lymphovenous anastomosis (LVA) market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 5.6.3. Vascularized lymph node transfer (VLNT)
    • 5.6.3.1. Vascularized lymph node transfer (VLNT) market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 5.6.4. Liposuction & debulking procedures
    • 5.6.4.1. Liposuction & debulking procedures market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
• 5.7. Pharmacological therapy
  • 5.7.1.1. Pharmacological therapy market estimates and forecasts for 2021 to 2033 (USD Million/Billion)

Chapter 6. Lymphedema Treatment Market: Affected Area Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Lymphedema Treatment Market: Affected Area Movement Analysis
• 6.3. Global Lymphedema Treatment Market Size & Trend Analysis, by Affected Area, 2021 to 2033 (USD Million/Billion)
• 6.4. Upper Extremity Lymphedema
  • 6.4.1. Upper extremity lymphedema market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
• 6.5. Lower Extremity Lymphedema
  • 6.5.1. Lower extremity lymphedema market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
• 6.6. Head & Neck Lymphedema
  • 6.6.1. Head & neck lymphedema market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
• 6.7. Genital & Truncal Lymphedema
  • 6.7.1. Genital & truncal lymphedema market estimates and forecasts for 2021 to 2033 (USD Million/Billion)

Chapter 7. Lymphedema Treatment Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Lymphedema Treatment Market: End Use Movement Analysis
• 7.3. Global Lymphedema Treatment Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million/Billion)
• 7.4. Hospitals
  • 7.4.1. Hospitals market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
• 7.5. Lymphedema Treatment Centers & Rehabilitation Clinics
  • 7.5.1. Lymphedema treatment centers & rehabilitation clinics market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
• 7.6. Ambulatory Surgical Centers (ASCs)
  • 7.6.1. Ambulatory surgical centers (ASCs) market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
• 7.7. Homecare Settings
  • 7.7.1. Homecare settings market estimates and forecasts for 2021 to 2033 (USD Million/Billion)

Chapter 8. Lymphedema Treatment Market: Regional Estimates & Trend Analysis by Type, Affected Area, Treatment Type, and End Use

• 8.1. Regional Dashboard
• 8.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
• 8.3. North America
  • 8.3.1. Market estimates and forecast, 2021 - 2033 (Revenue, USD Million/Billion)
  • 8.3.2. U.S.
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Competitive scenario
    • 8.3.2.3. Regulatory framework
    • 8.3.2.4. Reimbursement scenario
    • 8.3.2.5. U.S. market estimates and forecasts, 2021 - 2033
  • 8.3.3. Canada
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Competitive scenario
    • 8.3.3.3. Regulatory framework
    • 8.3.3.4. Reimbursement scenario
    • 8.3.3.5. Canada market estimates and forecasts, 2021 - 2033
  • 8.3.4. Mexico
    • 8.3.4.1. Key country dynamics
    • 8.3.4.2. Competitive scenario
    • 8.3.4.3. Regulatory framework
    • 8.3.4.4. Reimbursement scenario
    • 8.3.4.5. Mexico market estimates and forecasts, 2021 - 2033
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Competitive scenario
    • 8.4.1.3. Regulatory framework
    • 8.4.1.4. Reimbursement scenario
    • 8.4.1.5. UK market estimates and forecasts, 2021 - 2033
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Competitive scenario
    • 8.4.2.3. Regulatory framework
    • 8.4.2.4. Reimbursement scenario
    • 8.4.2.5. Germany market estimates and forecasts, 2021 - 2033
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Competitive scenario
    • 8.4.3.3. Regulatory framework
    • 8.4.3.4. Reimbursement scenario
    • 8.4.3.5. France market estimates and forecasts, 2021 - 2033
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Competitive scenario
    • 8.4.4.3. Regulatory framework
    • 8.4.4.4. Reimbursement scenario
    • 8.4.4.5. Italy market estimates and forecasts, 2021 - 2033
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Competitive scenario
    • 8.4.5.3. Regulatory framework
    • 8.4.5.4. Reimbursement scenario
    • 8.4.5.5. Spain market estimates and forecasts, 2021 - 2033
  • 8.4.6. Denmark
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Competitive scenario
    • 8.4.6.3. Regulatory framework
    • 8.4.6.4. Reimbursement scenario
    • 8.4.6.5. Denmark market estimates and forecasts, 2021 - 2033
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Competitive scenario
    • 8.4.7.3. Regulatory framework
    • 8.4.7.4. Reimbursement scenario
    • 8.4.7.5. Sweden market estimates and forecasts, 2021 - 2033
  • 8.4.8. Norway
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Competitive scenario
    • 8.4.8.3. Regulatory framework
    • 8.4.8.4. Reimbursement scenario
    • 8.4.8.5. Norway market estimates and forecasts, 2021 - 2033
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Competitive scenario
    • 8.5.1.3. Regulatory framework
    • 8.5.1.4. Reimbursement scenario
    • 8.5.1.5. Japan market estimates and forecasts, 2021 - 2033
  • 8.5.2. India
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Competitive scenario
    • 8.5.2.3. Regulatory framework
    • 8.5.2.4. Reimbursement scenario
    • 8.5.2.5. India market estimates and forecasts, 2021 - 2033
  • 8.5.3. China
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Competitive scenario
    • 8.5.3.3. Regulatory framework
    • 8.5.3.4. Reimbursement scenario
    • 8.5.3.5. China market estimates and forecasts, 2021 - 2033
  • 8.5.4. South Korea
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Competitive scenario
    • 8.5.4.3. Regulatory framework
    • 8.5.4.4. Reimbursement scenario
    • 8.5.4.5. South Korea market estimates and forecasts, 2021 - 2033
  • 8.5.5. Australia
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Competitive scenario
    • 8.5.5.3. Regulatory framework
    • 8.5.5.4. Reimbursement scenario
    • 8.5.5.5. Australia market estimates and forecasts, 2021 - 2033
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Competitive scenario
    • 8.5.6.3. Regulatory framework
    • 8.5.6.4. Reimbursement scenario
    • 8.5.6.5. Thailand market estimates and forecasts, 2021 - 2033
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Competitive scenario
    • 8.6.1.3. Regulatory framework
    • 8.6.1.4. Reimbursement scenario
    • 8.6.1.5. Brazil market estimates and forecasts, 2021 - 2033
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Competitive scenario
    • 8.6.2.3. Regulatory framework
    • 8.6.2.4. Reimbursement scenario
    • 8.6.2.5. Argentina market estimates and forecasts, 2021 - 2033
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Competitive scenario
    • 8.7.1.3. Regulatory framework
    • 8.7.1.4. Reimbursement scenario
    • 8.7.1.5. South Africa market estimates and forecasts, 2021 - 2033
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Competitive scenario
    • 8.7.2.3. Regulatory framework
    • 8.7.2.4. Reimbursement scenario
    • 8.7.2.5. Saudi Arabia market estimates and forecasts, 2021 - 2033
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Competitive scenario
    • 8.7.3.3. Regulatory framework
    • 8.7.3.4. Reimbursement scenario
    • 8.7.3.5. UAE market estimates and forecasts, 2021 - 2033
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Competitive scenario
    • 8.7.4.3. Regulatory framework
    • 8.7.4.4. Reimbursement scenario
    • 8.7.4.5. Kuwait market estimates and forecasts, 2021 - 2033

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
  • 9.2.1. Innovators
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Tactile Medical
    • 9.3.3.1. Company overview
    • 9.3.3.2. Financial performance
    • 9.3.3.3. Product benchmarking
    • 9.3.3.4. Strategic initiatives
  • 9.3.4. medi GmbH & Co. KG
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. SIGVARIS GROUP
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. BIOCOMPRESSION SYSTEMS
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. AIROS Medical, Inc.
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. L&R Group
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Huntleigh Healthcare Limited (Getinge AB)
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Koya Medical
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. 3M (Solventum)
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. Juzo
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. JOBST (Essity)
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Product benchmarking
    • 9.3.13.4. Strategic initiatives
  • 9.3.14. ImpediMed Limited and ImpediMed Inc.
    • 9.3.14.1. Company overview
    • 9.3.14.2. Financial performance
    • 9.3.14.3. Product benchmarking
    • 9.3.14.4. Strategic initiatives
  • 9.3.15. Lympha Press (Mego Afek)
    • 9.3.15.1. Company overview
    • 9.3.15.2. Financial performance
    • 9.3.15.3. Product benchmarking
    • 9.3.15.4. Strategic initiatives
• 9.4. Estimated Company Market Share Analysis, 2025
• 9.5. List of Other Key Market Players